Similar articles for PMID: 23867199

Year	Number of Results
1993	1
1995	2
1999	1
2005	1
2006	2
2007	1
2008	1
2009	1
2010	1
2011	1
2012	4
2013	3
2014	7
2015	11
2016	12
2017	11
2018	11
2019	19
2020	8
2021	3
2022	3
2023	2
2024	0

1

New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease.

Calabresi P, Castrioto A, Di Filippo M, Picconi B. Calabresi P, et al. Lancet Neurol. 2013 Aug;12(8):811-21. doi: 10.1016/S1474-4422(13)70118-2. Lancet Neurol. 2013. PMID: 23867199 Review.

2

Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease.

Kim M, Cho KH, Shin MS, Lee JM, Cho HS, Kim CJ, Shin DH, Yang HJ. Kim M, et al. Int J Mol Med. 2014 Apr;33(4):870-8. doi: 10.3892/ijmm.2014.1656. Epub 2014 Feb 13. Int J Mol Med. 2014. PMID: 24535622

3

Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.

Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, Thompson L, Halliday G, Kirik D. Hall H, et al. Brain. 2014 Sep;137(Pt 9):2493-508. doi: 10.1093/brain/awu193. Epub 2014 Jul 24. Brain. 2014. PMID: 25062696

4

Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.

Choi WS, Kim HW, Tronche F, Palmiter RD, Storm DR, Xia Z. Choi WS, et al. Sci Rep. 2017 Mar 22;7:44989. doi: 10.1038/srep44989. Sci Rep. 2017. PMID: 28327638 Free PMC article.

5

Neurotrophic factors for the treatment of Parkinson's disease.

Sullivan AM, Toulouse A. Sullivan AM, et al. Cytokine Growth Factor Rev. 2011 Jun;22(3):157-65. doi: 10.1016/j.cytogfr.2011.05.001. Cytokine Growth Factor Rev. 2011. PMID: 21689963 Review.

6

Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.

O'Keeffe GW, Sullivan AM. O'Keeffe GW, et al. Parkinsonism Relat Disord. 2018 Nov;56:9-15. doi: 10.1016/j.parkreldis.2018.06.025. Epub 2018 Jun 19. Parkinsonism Relat Disord. 2018. PMID: 29934196 Review.

7

Synaptic dysfunction in Parkinson's disease.

Picconi B, Piccoli G, Calabresi P. Picconi B, et al. Adv Exp Med Biol. 2012;970:553-72. doi: 10.1007/978-3-7091-0932-8_24. Adv Exp Med Biol. 2012. PMID: 22351072 Review.

8

Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.

Korecka JA, Moloney EB, Eggers R, Hobo B, Scheffer S, Ras-Verloop N, Pasterkamp RJ, Swaab DF, Smit AB, van Kesteren RE, Bossers K, Verhaagen J. Korecka JA, et al. J Neurosci. 2017 Sep 27;37(39):9361-9379. doi: 10.1523/JNEUROSCI.0084-17.2017. Epub 2017 Aug 21. J Neurosci. 2017. PMID: 28842419 Free PMC article.

9

Insights into the structure and function of the hippocampal formation: Relevance to Parkinson's disease.

Györfi O , Nagy H , Bokor M , Kéri S . Györfi O , et al. Ideggyogy Sz. 2018 Jan 30;71(1-02):15-24. doi: 10.18071/isz.71.0015. Ideggyogy Sz. 2018. PMID: 29465896 Free article. Review. English.

10

Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson's disease.

Virachit S, Mathews KJ, Cottam V, Werry E, Galli E, Rappou E, Lindholm P, Saarma M, Halliday GM, Shannon Weickert C, Double KL. Virachit S, et al. Brain Pathol. 2019 Nov;29(6):813-825. doi: 10.1111/bpa.12730. Epub 2019 Jun 14. Brain Pathol. 2019. PMID: 31033033 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

96 results

Results by year